Could a Low-Dose drug ease POTS fatigue? new trial aims to find out

NCT ID NCT05363514

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether low dose naltrexone (LDN) can reduce fatigue in people with Postural Orthostatic Tachycardia Syndrome (POTS). Eighty participants will receive either LDN or a placebo for 4 months. The goal is to see if LDN improves fatigue and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

low dose naltrexone (LDN)

What this could lead to

If it works, this could point toward a new treatment for fatigue in POTS patients, improving their daily quality of life.

What could go wrong

This is a small pilot study, so results may not be conclusive. The drug may not reduce fatigue more than placebo, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postural orthostatic tachycardia syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••